Chad Brinkley, BA, Board Member and CEO
Mr. Brinkley is the former Business Development Manager for the Center for Advancement of Science in Space (CASIS) and is currently Managing Partner at ProXopS, LLC. He also serves as a voting member of ChemoSen3D’s Board of Directors.
Brad Whitfield, MBA, Business Operations
Experienced Business Development and Operations Executive with strong skills in Negotiation, Petroleum, Gas, Operations Management, P&L management, and Sales. Graduate of Appalachian State University with a Bachelor of Science.
Christina van Lier, PhD, Chief Scientist
Dr. van Lier is the Senior Scientist at ChemoSen3D. Highly experienced in pharmacogenomics, molecular diagnostics, microbiome, and infectious disease testing spaces. She received her PhD in Microbiology and Immunology at the University of Texas Medical Branch, working with select agents at the Galveston National Laboratory.
Kirk Hollingshead, CFO
Mr. Hollingshead is the Chief Financial Officer at ChemoSen3D. He brings over 20 years of experience in finance and project management to the Company. In his prior role, he served clients in the aerospace, biomedical, energy, and technology sectors. His expertise includes business strategy, risk assessment, financial controls, compliance, and fraud detection.
Chad Brinkley, BA, Board Member and CEO
Mr. Brinkley is the former Business Development Manager for the Center for Advancement of Science in Space (CASIS) and is currently Managing Partner at ProXopS, LLC. He also serves as a voting member of ChemoSen3D’s Board of Directors.
Glauco Souza, PhD
Co-Founder, Director, former President and CSO of Nano3D Biosciences, and now Director of Global Business Development and Innovation at Greiner Bio-one (GBO). A pioneer in 3D cell culture, he holds significant influence in the field. He is instrumental in providing technical and innovation. Dr. Souza has an extensive academic background, including a B.S. in Chemistry, and M.S. and Ph.D. in Physical Chemistry from The George Washington University.
Thomas C. Killian, PhD
A distinguished academic background including a BA in Physics from Harvard University and a PhD in atomic physics from the Massachusetts Institute of Technology. Dr. Killian is currently the Dean for the Wiess School of Natural Sciences at Rice University. His research focuses on the properties of matter at ultra-low temperatures. He is a co-founder of both ChemoSen3D and Incellerate.
Mathew Lenhart
Mr. Lenhart is an Energy Trader with two decades of experience and a background in private company investing. He received his BS from Louisiana State University.
Leonardo Dias, MBA
Mr. Dias brings extensive experience in finance, cultivated over years of dedicated work in the field. He has held key roles such as CFO and IRO in publicly listed companies within the energy and telecommunications sectors. Mr. Dias earned his bachelor’s degree in Economics from the University of Brasília (UnB) and completed his MBA at The George Washington University’s School of Business and Public Management (SBPM).
Timothy Spicer, PhD
Dr. Spicer is currently the co-director of the Herbert Wertheim University of Florida Scripps Institute HTS Center in the Department of Molecular Medicine. With over 32 years of drug discovery experience, including a decade at Bristol-Myers Squibb, he brings a wealth of knowledge to the board. Dr. Spicer has authored over 150 drug-discovery related publications and holds 8 patents, including those for clinically useful drugs.
Laurence Cooper, MD, PhD
Dr. Cooper holds board certification in pediatric hematology and oncology. He recently served as Chief Executive Officer of Alaunos Therapeutics (NYSE:TCRT), where he worked on non-viral gene modification of T cells. His prior extensive experience at MD Anderson includes roles as a tenured professor, Section Chief of Cell Therapy, and Associate Director of the Center for Cancer Immunology Research. Dr. Cooper holds both an MD and a PhD from Case Western Reserve University.
Jeanne L. Becker, PhD
Dr. Becker serves as a scientific consultant for ChemoSen3D. Her impressive background includes being the founding President, CEO, and Executive Director of CASIS. Additionally, she was Chief Science Officer at Astrogenetix, Inc., where she was actively involved in using microgravity conditions to research novel therapeutics and vaccines. Dr. Becker’s academic experience includes faculty positions at Baylor College of Medicine and the University of South Florida College of Medicine.
